Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Dodge

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Cancer Research|March 25, 1992
Overexpression and mutation of p53 in endometrial carcinomaM F Kohler, A Berchuck, A M Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administeredJ C Byrd, R K Dodge, A Carroll, et al.
Blood|December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Blood|August 1, 2002
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Richard K Dodge, et al.
Blood|August 26, 1998
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111R A Larson, R K Dodge, C A Linker, et al.
Radiation Research|February 1, 1997
Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressureJ S Hahn, R D Braun, M W Dewhirst, et al.
Blood|July 27, 2001
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineR M Stone, D T Berg, S L George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|November 26, 1999
The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapyL R Prosnitz, P Maguire, J M Anderson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 2002
Gastrointestinal toxicity of transperineal interstitial prostate brachytherapySong K Kang, Rachel H Chou, Richard K Dodge, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Cancer Research|March 25, 1992
Overexpression and mutation of p53 in endometrial carcinomaM F Kohler, A Berchuck, A M Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administeredJ C Byrd, R K Dodge, A Carroll, et al.
Blood|December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Blood|August 1, 2002
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Richard K Dodge, et al.
Blood|August 26, 1998
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111R A Larson, R K Dodge, C A Linker, et al.
Radiation Research|February 1, 1997
Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressureJ S Hahn, R D Braun, M W Dewhirst, et al.
Blood|July 27, 2001
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineR M Stone, D T Berg, S L George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|November 26, 1999
The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapyL R Prosnitz, P Maguire, J M Anderson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 2002
Gastrointestinal toxicity of transperineal interstitial prostate brachytherapySong K Kang, Rachel H Chou, Richard K Dodge, et al.
Pageof 13